In a nationwide study of women with "triple-negative" breast cancer, adding the chemotherapy drug carboplatin or the angiogenesis inhibitor Avastin to standard chemotherapy drugs brought a sharp increase in the number of ...
Dec 13, 2013
1
0
(HealthDay)—Monica Barlow, a 35-year-old from Maryland, was training for a half-marathon when she noticed she couldn't shake a bad cough and ongoing fatigue. After a couple of rounds of antibiotics from an urgent care clinic ...
Apr 18, 2013
0
0
Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast ...
Apr 8, 2013
0
0
More than half of all patients with ovarian cancer experience recurrent disease and will eventually fail to respond to chemotherapy. The failure of chemotherapy is usually due to the development of resistance to the two main ...
Nov 29, 2012
0
0
(HealthDay)—A phase I trial of dasatinib combined with paclitaxel and carboplatin has determined the optimal dose of dasatinib and suggested some efficacy in women with advanced or recurrent ovarian cancer, according to ...
Nov 19, 2012
0
0
New cancer drugs must be thoroughly tested in preclinical models, often in mice, before they can be offered to cancer patients for the first time in phase I clinical trials. Key components of this process include pharmacokinetic ...
Sep 19, 2012
0
0
(Medical Xpress)—Researchers from the University of Dundee have discovered that measuring how active a gene is could predict which women with ovarian cancer will benefit from platinum-based chemotherapy drugs - a common ...
Sep 19, 2012
0
0
(HealthDay) -- For patients with non-small-cell lung cancer (NSCLC) who undergo neoadjuvant platinum-based chemotherapy, tissue platinum concentrations correlate positively with improved outcome, according to a study published ...
Aug 14, 2012
0
0
(HealthDay) -- For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with surgery alone, ...
May 31, 2012
0
0
Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients ...
Apr 17, 2012
0
0
